ArticleInfection and drug resistance2024
Epidemiology and Risk Factors of Candidemia a 8-Year Retrospective Study from a Teaching Hospital in China.
Article in Infection and drug resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Trial
- WHO Global Antimicrobial Resistance Surveillance System (GLASS) for monitoring bloodstream infections due toEClinicalMedicine · 2026Article
- Comparison of candidemia caused by Candida auris and non-auris Candida spp.: a retrospective cohort study on clinical characteristics, risk factors, and antifungal resistance profiles.BMC infectious diseases · 2026Article
- Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.BMC infectious diseases · 2026Article
- Epidemiology, Antifungal Susceptibility, and in-Hospital Mortality of Candidemia in a Tertiary Hospital of China: A 10-Year Retrospective Analysis.Infection and drug resistance · 2026Article
- Species Distribution, Antifungal Resistance, and Risk Factors ofInfection and drug resistance · 2026Article
- Community-Onset Fungemias: Epidemiology and Genomic Characterization at a Tertiary-Care Hospital in Barcelona, Spain.Journal of fungi (Basel, Switzerland) · 2025Article
- Epidemiological Characteristics and Mortality Predictors of Candidemia Due toJournal of fungi (Basel, Switzerland) · 2025Article
- Molecular characterization of Echinocandin resistance and the CHS3-mediated adaptive response in Candida glabrata bloodstream infections in Eastern China.BMC microbiology · 2025Article
- Epidemiological characteristics, antifungal susceptibility, and mortality factors of candidemia in adults at a tertiary teaching hospital in Zunyi, China (2016-2023).BMC infectious diseases · 2025Article
- Changing Epidemiology ofPathogens (Basel, Switzerland) · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Clinical manifestations and treatment of candidemia caused by different Candida species: a retrospective study.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We investigated the Epidemiology, risk factors and outcomes of Candida bloodstream infection. Methods: The electronic laboratory records data of patients with candidemia (2015-2022) were collected. We used univariate and multivariate logistic regression to determine the risk factors of candidemia. Results: Of the 134 patients with candidemia, the most prevalent species were Conclusion: The incidence rate and the mortality rate of candidemia are high, and lower azole susceptibility was found in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.